In a move that sent ripples through the pharma trading desk, the Indian government has set a 30% ceiling on trade margins for non‑scheduled cancer drugs, a figure that could compress earnings across the sector.
The cap aligns with a broader push to curb drug prices, but it also mirrors earlier price‑control moves on cardiac stents that failed to reduce out‑of‑pocket costs. Analysts note that a 30% margin restriction could shave roughly ₹1,200 crore from the industry's top‑line this fiscal year, though the exact hit will vary by company and drug portfolio.
Ashwin Sapra of Trilegal warned that the government may extend the cap beyond cancer drugs, potentially tightening margins on a wider range of therapies. "If the policy is applied indiscriminately, pharma firms could see a 15‑20% squeeze on their operating margins," Sapra said, citing industry data from the last quarter.
The Supreme Court’s October 12 hearing will decide whether the government can broaden the framework, while the NSE’s Pharma Index dipped 0.7% on the news. Investors are watching for guidance on whether the cap will be binding or subject to a phased implementation.